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Background: The tumor microenvironment (TME) is critical to every aspect of cancer biology. 
Organotypic tumor slice cultures (TSCs) preserve the original TME and have demonstrated utility in 
predicting drug sensitivity, but the association between clinicopathologic parameters and in vitro TSC 
behavior has not been well-defined. 
Methods: One hundred and eight fresh tumor specimens from liver resections at a tertiary academic center 
were procured and precisely cut with a Vibratome to create 250 μm × 6 mm slices. These fixed-dimension 
TSCs were grown on polytetrafluoroethylene inserts, and their metabolic activities were determined by a 
colorimetric assay. Correlation between baseline activities and clinicopathologic parameters was assessed. 
Tissue CEA mRNA expression was determined by RNAseq. 
Results: By standardizing the dimensions of a slice, we found that adjacent tumor slices have equivalent 
metabolic activities, while those derived from different tumors exhibit >30-fold range in baseline MTS 
absorbances, which correlated significantly with the percentage of tumor necrosis based on histologic 
assessment. Extending this to individual cancers, we were able to detect intra-tumoral heterogeneity over a 
span of a few millimeters, which reflects differences in tumor cell density and Ki-67 positivity. For colorectal 
cancers, tissue CEA expression based on RNAseq of tumor slices was found to correlate with clinical 
response to chemotherapies.
Conclusions: We report a standardized method to assess and compare human cancer growth ex vivo 
across a wide spectrum of tumor samples. TSC reflects the state of tumor behavior and heterogeneity, thus 
providing a simple approach to study of human cancers with an intact TME. 
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Introduction
In the current era of molecular oncology, patient-derived 
models that can accurately inform clinical decisions are 
urgently needed. Cancer is a diverse collection of diseases 
with enormous biologic and genomic heterogeneity, thus 
precision medicine, i.e., matching the right drugs with the 
right patients, has been an ongoing challenge. Advances in 
the molecular profiling of tumors through next-generation 
sequencing have led to new treatment paradigms with 
astonishing results for select patients, but it is estimated that 
fewer than 5% of patients with advanced cancers currently 
benefit from this approach (1). Many reasons contribute 
to this lackluster result, including a shortage of functional 
assays, the absence of effective therapies targeting common 
cancer genes such as RAS and p53, and the emergence 
of resistance stemming from functional compensation by 
other genes (2-4). Further, a single mutation may play 
different roles in different tumors, as highlighted by the 
variable response of BRAF (V600E)-associated non-
melanoma cancers to the BRAF inhibitor vemurafenib (5). 
At present, therapeutic decisions are based on a limited set 
of ‘actionable’ genomic data, without a full understanding 
of its biologic significance. Thus, a lack of individualized 
functional assays is a major shortcoming in the current 
practice of precision oncology. 
Human cancer models have become more prevalent with 
the increasing availability of organoid technology and in vivo 
patient-derived xenograft (PDX) mouse models (6,7). While 
these methods have yielded valuable biologic insights, one 
shared pitfall of these techniques is the inability to maintain 
the original tumor microenvironment (TME). Organotypic 
tissue slice cultures (TSCs) have been used for decades to study 
the physiologic properties of intact tissues, such as those of 
the central nervous system (8). Recent studies using TSCs as 
an ex-vivo model to predict drug sensitivity in cancer therapy 
have led to renewed interest in this platform, with investigators 
demonstrating preservation of the TME, molecular signaling, 
and treatment responses (9-12). Recently, we reported that 
slices from human pancreatic cancers remain viable in vitro 
and retain their TME, including the local immune milieu, 
thus allowing investigations of tumor immunology (13). 
Widespread application of TSCs in personalized oncology 
has lagged due to the absence of standardized methods for 
comparison between samples. Furthermore, there has been a 
paucity of evidence demonstrating that organotypic cultures 
reflect clinical characteristics of human cancers. Here we 
report a simple protocol that can be applied to diverse solid 
human gastrointestinal malignancies, and demonstrate the 
biologic relevance of TSCs by comparing in vitro growth 
properties with clinical and pathologic parameters. Using 
standardized readouts, this system allows us to compare and 
characterize inter- and intra-tumoral heterogeneity that 
correlates with the biologic state of the disease.
Methods
Subjects and clinical data 
Patients undergoing liver resection for primary or 
metastatic tumors were consented for tissue donation under 
IRB-approved protocols (University of Washington IRB 
#1852 and #1666). Fresh biospecimens were collected from 
a total of 108 patients over a two-year period, along with 
relevant de-identified clinical data. 
Sample preparation 
Sterile specimens from hepatectomies were processed 
immediately at the completion of resection under 
the direction of the surgeons (JO Park, RS Yeung) in 
consultation with Pathology staff (M Yeh). To maintain 
maximal sterility of the specimens, the latter were placed 
in a sterile field within the operating room. Following the 
directives of the pathology representative, ‘to-be-discarded’ 
tissues were procured in a sterile environment, usually 
within 10 minutes of the resection. 
Tissue procurement 
In order to establish a reproducible protocol that allows for 
comparison between samples, we aimed to generate tissue 
slices of a fixed volume. Six-mm tissue cores were procured 
from specimens using a sterile biopsy punch (Integra 
Miltex, York, PA), and immediately placed in cold Belzer-
UW solution (Bridge to Life Ltd., Columbia, SC) prior 
to transfer to research laboratories. We found that 6-mm 
cores are optimal for tumors >2 cm without interfering with 
clinical diagnosis. In our hands, smaller cores down to 4-mm 
worked equally well although the signals from the MTS 
assay were proportionally reduced.
Precision-cut slices 
Please refer to Supplemental Methods for step-by-step 
protocol. Briefly, 250 µm thick tumor slices were cut using 
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a Leica VT 1200S vibrating microtome (Leica Biosystems 
Nussloch GmbH, Germany) with the following settings: 
amplitude 2–3 mm and speed 0.5–1.5 mm/s, depending 
on tissue consistency. Tissue slices were washed with 
Williams’ Media E (Gibco, Grand Island, NY, USA), placed 
on Millicell Cell Culture Inserts (0.4 µm PTFE, EMD 
Millipore, Burlington, MA) in 24-well cell culture plates 
containing growth media, and incubated at 37 ℃ in 5% 
CO2 on a lab rocker set at 20 rotations/min. 
Culture conditions 
Tumor slices were cultured in Williams’ Media E containing 
nicotinamide (12 mmol/L), L-ascorbic acid 2-phosphate 
(50 mg/mL), D-(+)-and Glucose (5 mg/mL) (Sigma-Aldrich, 
St. Louis, MO, USA); Sodium Bicarbonate (2.5%), HEPES 
(20 mmol/L), Sodium Pyruvate (1 mmol/L), Glutamax (1%), 
and Penicillin Streptomycin (0.4%) (Gibco, Grand Island, 
NY, USA); ITS + Premix (1%), Human EGF (20 ng/mL) 
(BD Biosciences, San Jose, CA, USA). Media were changed 
one day after slicing and then every 2–3 days.
MTS assay 
Cell viability was assessed using the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium; MTS) (Promega, Fitchburg, WI, USA). Slices 
were incubated with MTS reagent while rocking at 37 ℃ 
for 2 or 3 hours. Media were transferred to a 96 well plate; 
absorbance was read at 490 nm and normalized to blanks 
(wells containing media and MTS without tissue slices). After 
MTS measurements, slices were either fixed in 10% formalin 
for 24 hours at 4 ℃ or placed back in their original cell 
inserts for continued culturing.
Histology and immunohistochemistry 
Fixed slices were embedded in paraffin, and 4µm thick 
sections were cut and placed on glass slides. Slides were 
stained with hematoxylin and eosin or processed for Ki-
67 immunohistochemistry (IHC) as described (14). To 
determine the Ki-67 positive fraction, the number of 
stained cells in at least 10 high power fields was counted.
Tumor cell transcriptomics 
Tumor slices were dissociated using the gentleMACS system 
(Miltenyi Biotec) and loaded on a Chromium instrument (10X 
Genomics) for single-cell RNA processing and 150 cycles 
of NextSeq500 (Illumina) sequencing. Reads were aligned 
to the human genome (GRCh38) and quantified using 
CellRanger v2 software. Tumor and non-tumor cells were 
computationally segregated by K-means clustering. Average 
CEACAM5, KRT20, and GAPDH expression levels were 
calculated for the EPCAM-expressing tumor cell clusters.
Statistical analyses 
R statistical software was used to develop a predictive model 
for high MTS values based on univariate and multivariate 
linear regression. Clinical covariates included age, sex, body 
mass index (BMI), history of smoking, any prior cancer 
treatments (surgical resection, radiofrequency ablation 
(RFA), chemotherapy, etc.), number of prior chemotherapy 
regimens, maximum liver tumor and primary tumor size of 
non-liver tumors, known metastatic disease, and number of 
tumors. Pathologic covariates included histology, maximum 
focus size and percent of viable/necrotic tissue in resected 
specimens, tumor regression grade (TRG) score, tissue 
fibrosis, tissue differentiation, maximum mitotic activity 
per high power field, and presence of nodal disease. Data 
were analyzed as continuous or discrete numeric variables, 
or as categorical or binary variables. Results for univariate 
and multivariate analyses are reported as slope coefficients 
for covariates of interest with 95% confidence intervals 
calculated from robust standard errors, P values for 
coefficients, and R2 values for each model. For the leave one 
out cross validation (LOOCV) analysis, results presented 
for comparison are the covariates included in each model, 
root-mean-squared errors (RMSE), and R2 values to 
compare predictive accuracy of the models. 
Results
Standardized assessment of human cancer tissue slice 
cultures
We set out to standardize our TSC platform, which allowed 
us to compare results between different tumor samples. As 
a quantitative readout, we used a colorimetric MTS assay 
to measure metabolic activity as our primary endpoint (15). 
This assay has the key advantage of low toxicity of MTS 
reagent, enabling multiple assessments of the same sample 
over time. In our experience, MTS absorbance remains 
stable over at least 3 repeated assays on any one sample 
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Figure 1 Standardized assessment of tumor slice cultures (TSCs) by precision cutting. (A) Workflow of the TSC platform from surgical 
specimen to slices. Left, representative tumor ‘wedge’ removed from surgical specimen; middle, 6-mm core from a punch biopsy; right, 
agarose-embedded cores set in Vibratome for slicing. Refer to Supplemental Methods for details; (B) comparison of baseline MTS 
absorbance with and without normalization to wet weight of slices from 2 cases of metastatic colorectal carcinoma (CRC). The table shows 
the variance of weight and absorbance measurements; (C) baseline MTS absorbance of 3 consecutive TSCs each from 4 different tumors 
without normalization to wet weight. HCC, hepatocellular carcinoma.
(data not shown). Next, we considered a number of 
methods to standardize MTS absorbance across different 
samples, including normalizing data to the wet weight of 
the slices, tissue volume, or total protein content. The 
latter method requires destruction of the sample, which 
would eliminate our ability to perform longitudinal studies 
such as drug sensitivity testing. Instead, we standardized 
the volume of tissue in our cultures using a precision-
cutting vibratome (Leica) to generate 250 µm thick slices 
from 6-mm cores, resulting in thin cylinders with a fixed 
volume of approximately 7 mm3 (Figure 1A). Baseline MTS 
measurements from consecutive slices from the same core 
were determined with and without normalization to the 
wet weights of individual slices. Figure 1B shows the results 
from two colorectal carcinoma (CRC) TSCs, highlighting 
significant variability in the wet weights of the slices, while 
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baseline MTS absorbances were highly homogeneous. 
In our hands, we found greater variability when the 
colorimetric absorbance was normalized to the wet weights 
of each slice. We attribute these results to our inability to 
precisely control the fluid or water content of slices during 
the weighing process while maintaining tissue viability, 
and postulate that this water content does not affect MTS 
values. Therefore, standardizing the slice dimensions without 
normalization had significantly less variance (Figure 1B table). 
We further confirmed that consecutive precision-cut slices 
from the same core of tumors of various histologies have 
nearly identical baseline MTS absorbance, obviating the need 
for additional normalization (Figure 1C). The simple step of 
standardizing the dimensions of the tumor slices allowed us 
to obtain highly reproducible assessment of the global ‘health’ 
of individual slices at baseline, thus enabling us to compare 
results among samples. 
Culture viability and integrity
Next, we examined the viability of TSCs over time. In 
the majority of cases, MTS measurements did not change 
over the first week in culture, as illustrated by the four 
independent tumors shown in Figure 2A. In further support 
of in vitro maintenance of growth, corresponding Ki-67+ 
fractions in each of these TSCs remained stable over the 
7-day period (Figure 2B). Figure 2C shows tumor histology 
and Ki-67 IHC in CRC, hepatocellular carcinoma (HCC), 
and intrahepatic cholangiocarcinoma (ICC) TSCs on days 
0 and 7, demonstrating that tumor architecture is preserved 
over time in TSCs, as are their proliferative activities. 
 In our experience with 108 consecutive tumors, we were 
able to generate TSCs in 89% of cases, thus making this 
technique highly reliable and efficient in creating patient-
specific cancer models for short-term investigation. Of the 
different tumor histologies from which we have generated 
TSCs, CRCs best maintain their ‘health’ in vitro, with a 
survival rate of 98%, while HCCs and ICCs show greater 
decline in their viability over the course of a week (65% 
and 71% survival, respectively). In an attempt to optimize 
conditions for HCC slices, we varied levels of serum, 
glucose, growth factors, and matrix in our cultures, but 
did not observe a consistent improvement in TSC survival 
over a two-week period with any of these changes (data not 
shown). As a result, we used uniform media and growth 
conditions for all tumor samples going forward (i.e., after 
our first 30 cases). Our current protocol is detailed in the 
Supplemental File. 
Correlation of TSC viability with clinical and pathologic 
parameters
We  t a b u l a t e d  b a s e l i n e  M T S  a b s o r b a n c e s  f r o m 
53 consecutive samples representing diverse tumor types 
following the standardization of our protocol; the clinical 
characteristics of the study cohort are summarized in Table S1. 
Figure 3 shows the mean baseline MTS absorbance from a 
minimum of three TSCs derived from 51 of these 53 cases; 
two cases in this initial cohort failed to cut due to poor tumor 
consistency. One can readily appreciate the wide range of 
baseline MTS values (i.e., 0.076 to 3.396), indicating the 
tremendous variability in growth and proliferative activity 
among different tumors at the time of resection.
We postulated that baseline MTS values reflect the 
variable biologic activities of the in vivo state, and may 
correlate with clinical and pathologic features. Univariate 
analyses based on the clinical and pathologic parameters 
shown in Table 1 identified three factors that correlated with 
in vitro viability scores (MTS values): (I) maximum tumor 
size on preoperative imaging (slope coefficient b =−0.083, 
P=0.02); (II) “other” histologic cancer type (b =−0.70, 
P=0.02); and 3) percent tumor necrosis on histologic 
examination (b =−0.012, P=0.005). Baseline MTS activities 
did not meaningfully differ between CRC, HCC, or ICC, 
nor did it correlate with age, sex, history of smoking, prior 
cancer treatment, number of neoadjuvant chemotherapy 
regimens, tumor regression grade, tissue fibrosis, tissue 
differentiation, mitotic activity, or nodal disease. Primary 
tumor size on preoperative imaging (b =−0.078, P=0.06), 
metastatic disease (b =−0.56, P=0.10), maximum viable 
focus size (b =−0.064, P=0.07), and percent tumor viability 
(b =0.006, P=0.10) trended toward associations with 
in vitro viability, but did not reach statistical significance on 
univariate analysis. 
A multivariate linear regression model chosen a priori, 
controlling for histologic cancer type, metastatic disease, 
maximum tumor size, maximum focus size, and percent 
necrosis, found that lower mean percent necrosis remained 
associated with higher baseline mean MTS (b =−0.012, 95% 
CI: −0.0211, −0.00273, P=0.01). Other covariates in the 
multivariate model did not show a significant association 
with mean MTS, though histologic cancer type of “other” 
still showed a trend of lower mean MTS compared to CRC 
as a reference (b =−0.471, P=0.08).
Comparing this model with several others for internal 
validity, we found a consistent association between mean 
percent necrosis and mean baseline MTS regardless of 
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Figure 2 Viability of tumor slices in vitro. Assessment of viability and proliferation by MTS assay (A) and Ki-67 expression (B) in tumor 
slices maintained in vitro for 7 days compared to baseline (day 0); (C) histologic appearances of the different tumor types based on H&E 
staining and Ki-67 immunostaining corresponding to samples highlighted in A. CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; 
ICC, intrahepatic cholangiocarcinoma. Original magnification 200×.
the number of other covariates included in the model. 
Using LOOCV with complete cases as described in 
methods, we determined that a model including metastatic 
disease, maximum tumor size, maximum viable focus 
size, and percent necrosis (Table 2) had the best predictive 
accuracy for in vitro viability, given it is lowest comparative 
RMSE and highest  comparat ive R2 (Model  #4 in 
Table S2). Together, these findings indicate that baseline 
MTS absorbance in TSCs mirrors tumor viability at the 
time of resection across all tumor types.
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Figure 3 Baseline MTS absorbance of fixed dimension tumor slices from 53 consecutive tumors. Values represent at least 3 biologic 
replicates taken randomly throughout each tumor. CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; ICC, intrahepatic 
cholangiocarcinoma; FNH, focal nodular hyperplasia; FLC, fibrolamellar carcinoma. 
Assessment of tumor heterogeneity 
While  there  i s  c lear  ev idence that  genomic  and 
transcriptomic heterogeneity exist within different parts of a 
given tumor, less is known about intra-tumoral variability in 
terms of metabolic activity. Our ability to detect metabolic 
differences among tumors (see Figure 3) suggested that our 
TSC method could also identify metabolic heterogeneity 
within tumors. We examined heterogeneity within tumors at 
two levels: regional differences that span several centimeters 
within a larger tumor, and local heterogeneity within a few 
millimeters. Figure 4A shows examples of baseline MTS 
values from separate tumor cores separated by at least 
1 cm obtained from tumors that were >3 cm in diameter, 
i.e., regional differences within tumors. Given that the 
central portion of a large solid tumor is often necrotic, 
we purposely took samples from the periphery of tumors, 
where tissue is expected to be more viable. Nonetheless, 
we observed significant differences in baseline MTS 
values from separate sites within each tumor in 4 out of 
5 cases (Figure 4A). We found that the variation in baseline 
metabolic activity correlates with the distribution of tumor 
vs. stromal components represented by each slice. Figure 4B 
illustrates the histology of the 3 sites from CRC-1 shown 
in Figure 4A. Of the 3 areas, Site 2 has extensive collagen 
deposition with only small areas of necrotic tumor cells, 
whereas Sites 1 and 3 contain significantly more viable 
tumor cells. Correspondingly, Site 2 had the lowest baseline 
MTS absorbance. On closer inspection, tumor cells occupy 
a significantly larger area of Site 1 compared to Site 
3 despite similar MTS absorbance. We thus hypothesized 
that tumor cells in site 3 were more mitotically and/or 
metabolically active than at the other two sites. Ki-67 IHC 
demonstrated a significantly higher fraction of Ki-67+ tumor 
cells in site 3 compared to site 1 (82% vs. 21%; Figure 4B). 
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Table 1 Univariate linear regression of average baseline MTS value with clinical and pathologic parameters
Clinical parameter Slope coefficient 95% confidence intervala P value R2
Age 0.0121 −0.00551 to 0.0299 0.173 0.0339
Male −0.0105 −0.4863 to 0.465 0.965 3.88e-5
BMI 0.0281 −0.0188 to 0.0749 0.235 0.0324
History of Smoking 0.0163 −0.457 to 0.457 0.945 7.58e-5
Prior treatment 0.215 -0.231 to 0.662 0.338 0.0157
Prior chemotherapy regimens 0.0027
0 (reference)
1 0.0895 −0.448 to 0.628 0.740
≥2 0.0246 −0.624 to 0.673 0.940
Maximum tumor size −0.0828* −0.15 to −0.0161 0.0159 0.081
Primary tumor size −0.0781 −0.016 to 0.00418 0.0623 0.054
Metastatic disease −0.557 −1.22 to 0.1107 0.1002 0.0304
Number of tumors −0.0141 −0.067 to 0.0388 0.594 0.00549
Pathologic parameter
Histologic cancer type 0.114
CRC (reference)
HCC −0.283 −0.973 to 0.406 0.413
ICC 0.0499 −0.685 to 0.785 0.892
Other −0.698* −1.28 to −0.119 0.0191
Maximum Focus Size −0.0644 −0.134 to 0.00512 0.0685 0.0558
Tumor Regression Grade 0.139 −0.0808 to 0.359 0.208 0.0404
Percent viability 0.006387 −0.00131 to 0.0141 0.1013 0.0651
Percent necrosis −0.0121* −0.0204 to −0.0038 0.0052 0.149
Fibrosis 0.222 −0.277 to 0.7195 0.374 0.159
Differentiation −0.158 −0.72 to 0.404 0.574 0.00796
MMA/hpf −0.0169 −0.0544 to 0.0207 0.369 0.00938
N Stage 0.0451
N0 (reference)
≥ N1 0.366 −0.173 to 0.905 0.179
Nx (unknown) 0.0253 −0.686 to 0.737 0.943
BMI, body mass index; CRC, colorectal cancer; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; MMA/hpf, 
maximum mitotic activity per high power field. a, calculated with robust standard errors; *, statistically significant. 
Table 2 Best predictive multivariate linear regression model of average baseline MTS value 
Model covariates Intercept Slope coefficient 95% confidence intervala P value R2 Adjusted R2
Metastatic disease 2.26 −0.732 −1.63 to 0.168 0.108 0.318 0.247
Maximum tumor size −0.0463 −0.131 to 0.0380 0.273
Maximum focus size −0.0624 −0.144 to 0.0197 0.132
Percent necrosis −0.0117 −0.0211 to −0.00220 0.0171
acalculated with robust standard errors.
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Figure 4 Baseline MTS value as an indicator of intra-tumoral heterogeneity. (A) Regional heterogeneity: MTS values from tumor cores 
obtained from 3 different sites within tumors >3 cm from 5 different patients. Each site is at least 1 cm from the others and is representd 
by at least 3 slices. *, P<0.05 compared to site 1; (B) histologic correlation with baseline MTS from CRC-1 shown in A. Top panels: H&E 
representing each of the 3 sites; bottom panel: Ki-67 IHC of cores from site 1 and site 3. Even though site 1 is more cellular than site 3, 
the proportion of Ki-67+ cells is significantly lower than site 3 (site 1: 21% vs. site 3: 82%). All photos are at 40× magnification; (C) local 
heterogeneity: Each tumor core was sectioned serially along its length and baseline MTS values were determined for each slice. Left column: 
Examples of tumor cores showing minor heterogeneity (<1 absorbance unit variation). Right column: Examples of tumor cores showing major 
heterogeneity (>1 absorbance unit variation). Examples of tumor histology indicated by the red circles are shown in two cases of CRC. Tumor 
cells are highlighted by purple stain. CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma.
0
1
2
3
0 0.5 1 1.5 2 2.5 3 3.5
M
TS
 (A
bs
)
Distance (mm)
0
1
2
3
0 0.5 1 1.5 2 2.5 3 3.5 4
M
TS
 (A
bs
)
Distance (mm)
M
in
or
 h
et
er
og
en
ei
ty
0.0
1.0
2.0
3.0
0 0.5 1 1.5 2 2.5 3 3.5 4
M
TS
 (A
bs
)
Distance (mm)
0.0
1.0
2.0
3.0
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
M
TS
 (A
bs
)
Distance (mm)
0
1
2
3
0 0.5 1 1.5 2 2.5
M
TS
 (A
bs
)
Distance (mm)
0
1
2
3
0 1 2 3 4 5
M
TS
 (A
bs
)
Distance (mm)
M
aj
or
 h
et
er
og
en
ei
ty
0
1
2
3
0 0.5 1 1.5 2 2.5
M
TS
 (A
bs
)
Distance (mm)
0
1
2
3
0 0.5 1 1.5 2 2.5 3 3.5 4
M
TS
 (A
bs
)
Distance (mm)
BA
C
0
0.5
1
1.5
2
2.5
3
CRC-1 CRC-2 HCC-1 HCC-2 ICC
Av
er
ag
e 
M
TS
 (A
bs
)
Site 1 Site 2 Site 3
Site 1 Site 2 Site 3
Site 1 Site 3
Ki-67
H&E
Kenerson et al. Human tumor slice culture
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(4):114 | http://dx.doi.org/10.21037/atm.2019.12.88
Page 10 of 12
These data suggest that both tumor cell density and their 
proliferative activities influence baseline MTS values in 
CRC metastases. 
To examine local heterogeneity within a span of 
millimeters, we analyzed consecutive tumor slices over 
the length of individual tissue cores (~1 cm). Of the eight 
samples analyzed in this fashion, four had similar MTS 
values (i.e., minor heterogeneity is defined as variability 
within 1 unit of absorbance) across the length of the 
cores, while the other 4 showed significant heterogeneity 
over similar distances (i.e., >1 unit of drift in absorbance; 
Figure 4C). Histologic examination revealed a correlation 
between MTS absorbance and the proportion of viable 
cancer cells within each slice (Figure 4C, bottom). Thus, 
within the CRC tumor microenvironment, tumor cells 
(as opposed to stromal cells) are the major contributor of 
metabolic activity in slice cultures.
Tumor CEA correlates with clinical response to 
chemotherapy
Baseline serum carcinoembryonic antigen (CEA) has been 
shown to be an independent poor prognostic factor in 
advanced CRC (16). Here, we measured mRNA expression 
of CEACAM genes from CRC tumor slices in culture 
for 72 hrs based on RNAseq. Figure 5 illustrates that 
tissue CEACAM5 (gene encoding CEA) mRNA levels 
were significant higher in tumor slices from patients who 
were deemed clinically chemo-resistant. In other words, 
CEACAM expression inversely correlated with clinical 
response. This was not due to differences in the viability 
of the slices between chemo-resistant and chemo-sensitive 
tumors, given comparable expression of GAPDH and 
cytokeratin 20 (KRT20) genes. 
Discussion
In this study we describe a standardized method to evaluate 
human-derived TSCs in vitro across a broad spectrum 
of primary and metastatic liver cancers. Specifically, we 
developed a simple and reproducible protocol that maintains 
tumor viability for days, and allows for comparison among 
fixed-volume samples generated by precision cutting with 
a vibratome. While previous studies have emphasized the 
utility of organotypic slice cultures to test drug sensitivity 
in individual cancers, few studies have compared biologic 
endpoints among different tumors. Here, we show that 
baseline MTS absorbance of fixed volume slices provides a 
quantitative measure of the metabolic activity that accurately 
reflects disease viability and biologic status of the tumor 
at the time of resection. Applying the MTS assay across 
different TSC samples provides a simple way to compare 
cancer metabolic activity and viability in a cohort of patients. 
In our experience of over 100 cases, we have optimized 
and standardized our protocol for multiple types of 
primary and secondary liver tumors. We have learned that 
consecutive slices of fixed dimensions have nearly identical 
metabolic/growth activity, and thus serve as biologic 
replicates in experiments. By the same token, we can exploit 
TSCs to evaluate tumor heterogeneity in human cancers. 
Tumor tissues that are separated by even a few millimeters 
can exhibit significant changes in MTS values, reflecting 
underlying differences in the distribution of tumor cells 
within a cancer. In our tumor samples from liver metastases, 
the majority of patients had received pre-operative systemic 
therapy. The correlation between baseline MTS absorbance 
and the amount of histologically necrotic tumor allows us 
to quantitatively gauge the effectiveness of neoadjuvant 
therapy at the time of resection, independent of standard 
pathologic evaluation. For CRCs, we also found that tissue 
CEA mRNA levels negatively correlated with clinical 
response to chemotherapies.
A key advantage of using TSC as a model of human 
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Figure 5 Tissue mRNA expression of CEA correlates negatively 
with clinical response to chemotherapies. Tumo slices from 
metastatic CRC in the liver were analyzed by RNAseq to 
determine level of expression of CEACAM5 gene that encodes 
CEA. Results are compared to those of cytokeratin 20 (KRT20) 
and a housekeeping gene, GAPDH. Response groups are based 
on clinical data from patients receiving chemotherapies prior the 
surgical resection. 
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cancer is the ease and efficiency in generating an in vitro 
system that preserves the tumor microenvironment. We 
have exploited this feature in addressing the immune 
landscape in human malignancies (13,17) that is not easily 
reproduced in other systems including cell lines, organoids, 
and PDX mice. There is no lag time associated with TSC; 
slices can be put to use almost immediately upon culture 
and without concerns for selection pressure. With a success 
rate of nearly 90% in establishing TSC in our sample 
set, the model provides a simple method to study human 
cancers while preserving the original spatial architecture 
and elements of the TME. 
There are a few important limitations in using the TSC 
platform. First and foremost is that the lifespan of tumor 
slices is finite and non-renewable, thus long-term or repeat 
experiments are limited. Efforts are currently underway to 
optimize cryopreservation methods such that the slices can 
be studied at any time. Not all tumors behave the same; 
in our experience, metastatic colorectal metastases are the 
most hardy to grow in vitro unless they have undergone 
extensive necrosis from prior chemotherapy. On the other 
hand, tumors such as hepatocellular carcinoma are more 
variable in their ability to remain viable long-term in 
culture. For any particular sample, there remains many 
conditions that can be fine-tuned for optimal growth 
including, but not limited to, components of the media, 
thickness of the slice, ambient oxygen level, and the extent 
of physical motion. Our protocol provides a starting point 
for anyone who wants to explore this method in their 
studies. Access to fresh, sterile tumor specimens is critical 
to creating TSCs, and at our Institution, this effort is led 
by surgeons who, in collaboration with pathologists, have 
developed a highly efficient practice of procuring samples 
without compromising clinical care. In the future, we 
anticipate modification of our technique to adopt core-
needle biopsies, which will expand the clinical applications 
greatly in the field of precision oncology by bridging ‘omics’ 
data with functional biologic assays.
In summary, our study highlights a simple, standardized 
method to generate TSCs from solid tumors using a fixed 
volume of tissue, which allows for sample comparison. Besides 
the ability to test drug sensitivity, properties inherent in the 
tumor slices provide biologic information that are clinically 
relevant. We show that TSCs provide a functional platform 
that is useful in detecting inter- and intra-tumor heterogeneity, 
a feature that needs to be taken into consideration in order to 
optimize treatment recommendations and improve outcome 
for individual cancers. 
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Supplemental methods
Reagents
Belzer UW Cold Storage Solution (Bridge to Life)
5 mL Eppendorf tubes (cat. no. 0030119487)
48-well cell culture plates (Corning, C3548)
24-well cell culture plates (Corning, C3527)
96-well assay plate—Corning Costar Assay Plate, clear, flat bottom, 9017
Millipore Cell Culture Inserts (PTFE 0.4µM pore) PICM01250 Millipore Sigma
#10 Scalpels (Exel International, 29550)
Sterile gauze (Covidien, Curity 3157)
Sterile petri dish (Fisher Scientific, FB0875713)
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS), (Promega,G3580)
UltraPure Low Melting Point Agarose (cat. no. 16520100)
DPBS (Gibco – 14190144)
Williams medium E (Gibco-Invitrogen cat# 12551-032)
L-Glutamine (Gibco-Invitrogen cat#25030-081)
Nicotinamide (Sigma N-0636)
Asorbic acid (Sigma cat# A8960)
Sodium Bicarbonate (Gibco-Invitrogen cat#15630-080)
D-Glucose (Sigma cat# G5767-500G)
Sodium Pyruvate (Gibco-Invitrogen cat#11360-070)
HEPES (Gibco-Invitrogen cat#15630080)
ITS + Premix (BD Biosciences cat#354352)
Penicillin-Streptomycin (Gibco-Invitrogen cat# 15140-122)
Human EGF (BD Biosciences cat# 354052) 
Microsette Six Compartment Biopsy Cassettes (Fisher, 15182705C)
Tools
Lieca VT 1200S Vibrating Microtome (Leica Biosystems, Germany) 
Blades (double edge, PTFE coated) (Ted Pella, 121-6)
Adhesive (Ted Pella, 7085-85-0) 
Debonder (Ted Pella, 75-52-5)
Rocker Model 55 Variable Speed (Reliable Scientific)
Sterile forceps
Sterile Curved Spatula
Microplate Reader (Molecular Devices, Optimax)
6-mm Disposable Biopsy Punch (Integra-Miltex 33-36)
Preparation of 2% agarose solution 
Add 1 gram of low melting point agarose to 25 mL of sterile dPBS in a sterile 250 ml Erlenmeyer flask. Microwave on low 
power until agarose has completely dissolved. Stop microwave and swirl liquid every 20 seconds so contents do not boil over. 
Let cool down slightly in 37-degree water bath and then add 25 mL of Williams Medium E. Leave in 37-degree water bath 
until ready to use. 
Supplementary
Preparation of modified WME 
Williams’ Media E containing:
nicotinamide (12 mmol/L)
L-ascorbic acid 2-phosphate (50 mg/mL)
D-(+)-and Glucose (5 mg/mL) 
Sodium Bicarbonate (2.5%)
HEPES (20 mmol/L) 
Sodium Pyruvate (1 mmol/L)
ITS premix (1%)
Glutamax (1%) or L-glutamine (1%)
Penicillin Streptomycin (0.4%) 
Human EGF (20 ng/mL) 
Procedure 
Preparation for slice experiment 
(I) Prepare 5 mL Eppendorf collection tube with 3 mL of Belzer UW Cold Storage Solution. Keep on ice. 
(II) Prepare wash buffer, WME media with 1% Penicillin Streptomycin.
(III) Prepare modified WME.
(IV) Transfer 400 µL of WME with 1% Penicillin Streptomycin into each well of a 48 well plates, depending on the 
number of slices desired, and place in tissue culture incubator. 
(V) Prepare 2% agarose solution and place in 37-degree water bath.
Collection of human tissue
(I) Criteria for research collection. 
i. Resection of primary or secondary liver tumors
ii. Tumor is greater than 2 cm in diameter
iii. Margins and pathologic assessment will not be compromised from the tissue collection.
(II) The specimen is placed on the sterile field immediately upon completion of the resection. In the presence of 
a pathology representative, a wedge of tumor tissue of ~1 cm thick is removed from the specimen using sterile 
instruments. This is done without sacrificing or violating any potential tissue or margins that are needed for clinical 
evaluation. 
(III) The tumor tissue wedge is cored using the 6-mm biopsy punch. Using non-tooth pick-ups, cores are placed directly in 
3 mL of ice-cold Belzer UW Cold Storage Solution in 5 mL Eppendorf tubes and placed on ice. To maximize tissue 
viability, cores are taken from the periphery of the tumor to avoid areas of central necrosis.
(IV) Tissue is transported on ice immediately to the lab for processing. These steps are usually completed within 
10 minutes of surgical resection.
Preparation of tissue
(I) Place buffer tray in holder and cover. Add ice around buffer tray. 
(II) Tissue cores are removed from UW solution with sterile forceps and placed in a sterile petri dish. 
(III) Excess liquid is dabbed off on sterile gauze.
(IV) Tissue cores can be directly glued to the specimen disc with adhesive for slicing.
i. Longer cores can be cut in half with sterile scalpel.
(V)  Or cores can be embedded in 2% agarose solution for slicing. 
i. Embedding in agarose is important for softer tissue cores. 
(V) Position core in the center of one well of a sterile 24 well plate.
(VI) Pipet 37 ℃, 2% agarose solution over top of core(s) in each well until tissue is entirely covered, place cover on plate, 
and place on ice.
(VII) Agarose will solidify in less than 5 min. 
(VIII) Once the agarose has solidified use a sterile scalpel or spatula to cut along the edge of the agarose in the well. With a 
scooping motion pop the embedded tissue course out of the well and onto a petri dish. 
(IX) Using a drop of superglue, glue the face of the embedded core that was on the bottom of the well directly to the 
specimen disc. Ensure that both the tissue and agarose are in contact with the adhesive. The top of the agarose will 
have a concave shape. 
(X) Up to 4 cores in agarose or 6 not it agarose can be glued to the specimen disc at one time for efficient slicing. 
(XI) The specimen disc is then placed in the buffer tray and the buffer tray is filled with ice cold Belzer UW solution. 
Preparation of tumor slices
(I) Place the ice tray onto the vibratome and secure.
(II) Rotate blade to position 2.
(III) Raise the stage up using the control pad until the blade touches the liquid in the buffer tray. 
(IV) Set cutting window using the control pad. 
(V) Once the window is set, using the run feature step down 250 microns at a time at a 1.5 mm/s until the blade reaches 
the tallest tissue core. 
(VI) Adjust settings on the vibratome depending on the consistency and integrity of the tissue (amplitude 2–3 mm, speed 
0.5–1.5 mm/s).
(VII) Once uniform 250 µm thick slices are obtained, gently scoop out of the bath using a sterile spatula or forceps. 
(VIII) Place each slice in one well of a 48 well dish containing prewarmed modified WME media. 
(IX) Each core and slice were assigned a numerical value so that the sequence and orientation of slices were tracked and 
documented. 
(X) Once a 48 well plate was filled with slices it was placed at 37 degrees on a rocker (20 rocks/minute) for 1–4 hours for 
washing. 
Determination of viability, MTS assay
(I) Thaw 5 mL aliquots of CellTiter 96 Aqueous One Solution in the 37-degree water bath. 
(II) Place 400 µL of modified WME into each well of a 48 well dish. 
(III) Transfer slices to individual wells. Keeping track of slice identification number. Keep 3 wells without slices for blanks.
(IV) Add 80 µL of CellTiter 96 Aqueous One Solution to each well of the plate. 
(V) Incubate plate on rocker for 3 hours. (Note: media and slice will change purple).
(VI) Transfer 200 µL of each blank and each slice well to a 96 well assay plate. 
(VII) Read plate at 490 nm, blanks are averaged and subtracted from the values of the slices. 
(VIII) At this point slices can be fixed or transferred back to initial Millicell insert for further culturing.
Preparation of tissue for histology
(I) Tissue slices are fixed in 400 µL of 10% formalin in a 48 well dish at 4 ℃ for 24 hours. 
(II) Tissue slices were placed in one compartment each of a six compartment microsette biopsy cassette. Cassettes were 
labeled with identification code of each slice in each compartment. Cassettes were placed in 70% ethanol. 
(III) Tissue was embedded in paraffin in the orientation placed in the cassette and 4 µm sections were cut and mounted on 
slides.
Table S1 Characteristics of patients listed in Figure 3
Tumor type All Participants
Primary liver tumors Metastatic liver tumors
HCC ICC HCC-ICC Other CRC Other
Total cases, n 53 7 6 2 5 25 8
Age, mean ± SD 
[range]
55±13 [26–77] 55±17 [25–77] 57±16 [36–69] 45.5±13.6 [28–63] 36.7±2.3 [34–38] 55.9±10.4 [37–71] 51.9±14.2 [36–72]
Male, n [%] 31 [57] 5 [71] 5 [83] 1 [50] 1 [20] 14 [56] 3 [38]
MTS, mean ± SD 1.50±0.84 1.39±0.81 1.72±0.9 1.6±0.19 1.7±0.67 1.52±0.85 0.9±0.22
HCC, hepatocellular carcinoma; ICC, intra-hepatic cholangiocarcinoma; CRC, colorectal carcinoma; SD, standard deviation.
Table S2 Comparative predictive accuracy of multiple multivariate 
models using leave-one-out cross-validation
Model # Model covariates RMSEa R2
Complete 
cases (n=53)
0 Age 
Male 
Histologic cancer type 
Metastatic disease 
Maximum tumor size 
Primary tumor size 
Maximum focus size 
% Necrosis
0.858 0.0366 39
1 Age 
Histologic cancer type 
Metastatic disease 
Maximum tumor size 
Primary tumor size 
Maximum focus size 
% Necrosis
0.864 0.0281 39
2* Histologic cancer type 
Metastatic disease 
Maximum tumor size 
Maximum focus size 
% Necrosis
0.760 0.130 43
3 Metastatic disease 
Maximum tumor size 
Maximum focus size 
% Necrosis 
N Stage
0.770 0.100 39
4** Metastatic disease 
Maximum tumor size 
Maximum focus size 
% Necrosis
0.727 0.159 43
5 Metastatic disease 
Maximum tumor size 
% Necrosis 
N Stage
0.828 0.0888 44
6 Metastatic disease 
Maximum tumor size 
% Necrosis
0.779 0.157 48
7 Histologic cancer type 
Maximum tumor size 
% Necrosis
0.79 0.142 48
8 Maximum tumor size 
% Necrosis
0.784 0.137 48
9 % Necrosis 0.807 0.0816 48
RMSE, root-mean-square error. a, Lower RMSE and higher 
R2 indicate better predictive accuracy for this data. *, Original 
model hypothesized a priori to be best predictive model. **, 
Model with best predictive accuracy.
